120 related articles for article (PubMed ID: 1857840)
1. [Heparin anticoagulant activity: new knowledge and future prospects].
Camici M; Giusti C; Evangelisti L
Recenti Prog Med; 1991 Apr; 82(4):209-18. PubMed ID: 1857840
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
4. Molecular weight of heparin versus biologic activity. Some additional considerations.
Losito R; Losito C
Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
[No Abstract] [Full Text] [Related]
5. [From heparin to heparins: toward new therapeutic perspectives?].
Molho P; Tobelem G
Biomed Pharmacother; 1987; 41(4):171-5. PubMed ID: 3620582
[TBL] [Abstract][Full Text] [Related]
6. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
Elgue G; Blombäck M; Olsson P; Riesenfeld J
Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
[TBL] [Abstract][Full Text] [Related]
7. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
8. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
9. The characteristics of anticoagulation by covalently immobilized heparin.
Miura Y; Aoyagi S; Kusada Y; Miyamoto K
J Biomed Mater Res; 1980 Sep; 14(5):619-30. PubMed ID: 7349668
[TBL] [Abstract][Full Text] [Related]
10. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacology of heparin].
Hoffmann A; Markwardt F
Z Gesamte Inn Med; 1979 Jan; 34(1):3-8. PubMed ID: 373277
[TBL] [Abstract][Full Text] [Related]
12. Standard and method independent units for heparin anticoagulant activities.
Hemker HC; Béguin S
Thromb Haemost; 1993 Nov; 70(5):724-8. PubMed ID: 8128425
[TBL] [Abstract][Full Text] [Related]
13. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
14. [Low molecular weight heparins].
Kher A; Bara L; Samama M
Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
[TBL] [Abstract][Full Text] [Related]
15. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
16. New antithrombin-based anticoagulants.
Desai UR
Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
[TBL] [Abstract][Full Text] [Related]
17. Synthetic heparin derivatives as new anticoagulant drugs.
de Kort M; Buijsman RC; van Boeckel CA
Drug Discov Today; 2005 Jun; 10(11):769-79. PubMed ID: 15922935
[TBL] [Abstract][Full Text] [Related]
18. Possible mechanism of the synergistic effect of heparin and dihydroergotamine.
Kakkar VV; Welzel D; Murray WJ; Malone P; Jones D
Am J Surg; 1985 Oct; 150(4A):33-8. PubMed ID: 4051120
[TBL] [Abstract][Full Text] [Related]
19. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
Wang ZM; Li L; Li B; Guo SY
Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
